ARTICLE | Clinical News
Dalbavancin regulatory update
February 17, 2014 8:00 AM UTC
FDA's Anti-Infective Drugs Advisory Committee will meet on March 31 to discuss an NDA from Durata for IV dalbavancin to treat acute bacterial skin and skin structure infections (ABSSSI). The second-ge...